Core Insights - Annexon, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people globally [1][3]. Company Overview - Annexon is advancing a next-generation platform of targeted immunotherapies aimed at addressing serious neuroinflammatory diseases [3]. - The company's scientific approach centers on C1q, a molecule that initiates a potent inflammatory pathway, which can lead to tissue damage when misdirected [3]. - Annexon's therapies are designed to halt classical complement-driven neuroinflammation at its source, aiming to provide significant functional benefits and alter disease progression [3]. - The mission of Annexon is to deliver transformative therapies to patients, enabling them to lead their best lives [3]. Upcoming Events - Douglas Love, the president and CEO of Annexon, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST [1]. - A live webcast of the presentation will be available on the company's Investors page, with a replay archived for 30 days post-event [2].